Bausch + Lomb Corporation reported first‑quarter 2026 results that surpassed analyst expectations, with total revenue of $1.244 billion—up 9% year‑over‑year and 6% on a constant‑currency basis—while operating income swung to $33 million from an operating loss of $83 million in the same quarter of 2025. Adjusted earnings per share rose to $0.08, beating the consensus estimate of $0.059 and marking a turnaround from the $0.15 loss reported a year earlier.
Segment‑level analysis shows Vision Care generated $711 million, Pharmaceuticals $305 million, and Surgical $228 million. The Pharmaceuticals segment, driven by strong sales of MIEBO and XIIDRA, contributed the largest share of the revenue increase, while Vision Care’s growth was supported by premium intra‑ocular lens sales. The Surgical segment’s $228 million revenue reflected steady demand for its product portfolio, offsetting modest headwinds in legacy product lines.
The $0.08 adjusted EPS beat was largely attributable to disciplined cost management and a favorable product mix. Operating income improvement was driven by higher margin contributions from the Pharmaceuticals and Vision Care segments, while the company maintained tight control over SG&A expenses. The combination of higher pricing power in key drug categories and efficient manufacturing helped lift profitability despite modest inflationary pressures.
Management raised its full‑year 2026 revenue guidance to $5.420 billion–$5.520 billion, an increase from the prior $5.375 billion–$5.475 billion range. The adjustment reflects confidence in continued demand for the company’s pharmaceutical franchise and surgical platform, as well as the impact of AI‑driven operational efficiencies that have expanded gross margin to 61.2% year‑over‑year. Adjusted EBITDA guidance was maintained at $1.010 billion–$1.060 billion, underscoring management’s belief that margin expansion will persist.
Analysts noted that the strong performance in the Pharmaceuticals segment, particularly the double‑digit growth of MIEBO and XIIDRA, underpins the company’s optimistic outlook. While some market participants expressed caution over broader macro‑economic uncertainty, the consensus view remains that Bausch + Lomb’s focus on high‑margin products and operational efficiencies positions it well for sustained growth.
The Q1 results and raised guidance signal a robust trajectory for Bausch + Lomb, with a clear emphasis on leveraging its pharmaceutical and surgical strengths while continuing to invest in AI‑enabled efficiencies. The company’s turnaround from a prior operating loss to a profitable quarter, coupled with a higher-than‑expected EPS, reinforces confidence in its strategic execution and long‑term value creation.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.